Cited by 207Protein Degradation and InhibitorsLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Open access

Hagner, Patrick R., Man, Hon-Wah, Fontanillo, Celia, Wang, Maria, Couto, Suzana, Breider, Mike, Bjorklund, Chad, Havens, Courtney G., Lu, Gang, Rychak, Emily, Raymon, Heather, Narla, Rama Krishna, Barnes, Leo, Khambatta, Gody, Chiu, Hsiling, Kosek, Jolanta, Kang, Jian, Amantangelo, Michael D., Waldman, Michelle, Lopez-Girona, Antonia, Cai, Ti, Pourdehnad, Michael, Trotter, Matthew, Daniel, Thomas O., Schafer, Peter H., Klippel, Anke, Thakurta, Anjan, Chopra, Rajesh, Gandhi, Anita K.·2015·Blood

DOI 10.1182/blood-2015-02-628669PMC PMC4528065

Open this paper in CoChat — free account Open PDF

Abstract

Key Points: CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity. CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2015-02-628669

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,847
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Self-citation
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
Feugier, P., Hoof, A. V., Sebban, C., Solal-Céligny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, É., Tilly, H., Morschhauser, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.131 · Cited by 1,487
New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
Armitage, J. O., & Weisenburger, D. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2780 · Cited by 1,259
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
Scott, D. W., Wright, G. W., Williams, P. M., Lih, C., Walsh, W. D., Jaffe, E. S., Rosenwald, A., Campo, E., Chan, W. C., Connors, J. M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536433 · Cited by 639
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate Tcells by inducing degradation of Tcell repressors Ikaros and Aiolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Self-citation
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
Barrans, S., Crouch, S., Smith, A. G., Turner, K., Owen, R. G., Patmore, R. D., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G. W., Xiao, W., Powell, J. I., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 541
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Self-citation
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R. J., Polikoff, J. A., Bouabdallah, R., Haïoun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G. R., Vose, J. M., Cole, C. E., Lam, W., McBride, K., Wride, K., PIETRONIGRO, D. D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3429 · Cited by 371
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project
Rimsza, L. M. (2004) · Blood · doi:10.1182/blood-2003-07-2365 · Cited by 343
Early hematopoietic lineage restrictions directed by Ikaros
Yoshida, T., Ng, S. Y., Zúñiga‐Pflücker, J. C., & Georgopoulos, K. (2006) · Nature Immunology · doi:10.1038/ni1314 · Cited by 324
ERK2 but Not ERK1 Induces Epithelial-to-Mesenchymal Transformation via DEF Motif-Dependent Signaling Events
Shin, S., Dimitri, C. A., Yoon, S.-O., Dowdle, W. E., & Blenis, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.020 · Cited by 299
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
Thiéblemont, C., Brière, J., Mounier, N., Voelker, H.-U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundström, C., Cogliatti, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4423 · Cited by 277
Treatment of Advanced Non-Hodgkin's Lymphoma with Recombinant Leukocyte a Interferon
Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F., Stevenson, H. C., Ochs, J. J., Bottino, G. C., SCHOENBERGER, C., Zeffren, J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411013111803 · Cited by 274
Aiolos promotes TH17 differentiation by directly silencing Il2 expression
Quintana, F. J., Jin, H., Burns, E. J., Nadeau, M., Yeste, A., Kumar, D., Rangachari, M., Zhu, C. Y., Xiao, S., Seavitt, J., et al. (2012) · Nature Immunology · doi:10.1038/ni.2363 · Cited by 259
Genome-wide Lineage-Specific Transcriptional Networks Underscore Ikaros-Dependent Lymphoid Priming in Hematopoietic Stem Cells
Ng, S. Y., Yoshida, T., Zhang, J., & Georgopoulos, K. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.014 · Cited by 258
Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis
Zhang, J., Jackson, A. F., Naito, T., Dose, M., Seavitt, J. R., Liu, F., Heller, E. J., Kashiwagi, M., Yoshida, T., Gounari, F., et al. (2011) · Nature Immunology · doi:10.1038/ni.2150 · Cited by 191
Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
Vaidya, R., & Witzig, T. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu109 · Cited by 187
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
Zhang, L., Kosek, J., Wang, M., Heise, C. C., Schafer, P. H., & Chopra, R. (2012) · British Journal of Haematology · doi:10.1111/bjh.12172 · Cited by 172
Self-citation
MYC and BCL 2 protein expression predicts survival in patients with diffuse large B ‐cell lymphoma treated with rituximab
Perry, A. M., Alvarado-Bernal, Y. L., Laurini, J. A., Smith, L. M., Slack, G. W., Tan, K. L., Sehn, L. H., Fu, K., Aoun, P. A., Greiner, T. C., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12763 · Cited by 166
Ikaros and Aiolos Inhibit Pre-B-Cell Proliferation by Directly Suppressing c-Myc Expression
Ma, S., Pathak, S., Mandal, M., Trinh, L., Clark, M. R., & Lu, R. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00224-10 · Cited by 138
Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a
Rosebeck, S., & Leaman, D. W. (2008) · APOPTOSIS · doi:10.1007/s10495-008-0190-0 · Cited by 131
Ikaros-CtIP Interactions Do Not Require C-terminal Binding Protein and Participate in a Deacetylase-independent Mode of Repression
Koipally, J., & Georgopoulos, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202079200 · Cited by 72
Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes
Farrugia, M. M., Duan, L., Reis, M., Ngan, B., & Berinstein, N. L. (1994) · Blood · doi:10.1182/blood.v83.1.191.191 · Cited by 54
Identification of XAF1 as a novel cell cycle regulator through modulating G2/M checkpoint and interaction with checkpoint kinase 1 in gastrointestinal cancer
Wang, J., Gu, Q., Li, M., Zhang, W., Yang, M., Zou, B., Chan, S., Qiao, L., Jiang, B., Tu, S., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp155 · Cited by 43
A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL
Czuczman, M. S., Davies, A. J., Linton, K., Wagner‐Johnston, N. D., Gascoyne, R. D., Eberhard, D. A., Salles, G., Witzig, T. E., Zinzani, P. L., Wright, G. W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.628.628 · Cited by 20
Relapsed and refractory aggressive NHL: Time for a change
Gangatharan, S. A., & Kuruvilla, J. G. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.05.029 · Cited by 17
Silencing of the I l2 gene transcription is regulated by epigenetic changes in anergic T cells
Bandyopadhyay, S., Montagna, C., & Macián, F. (2012) · European Journal of Immunology · doi:10.1002/eji.201142307 · Cited by 16
CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma
Ribrag, V., Damien, S., Gharibo, M. M., Gironella, M., Santoro, A., Rasco, D. W., Edenfield, W. J., Wei, X., James, A. J., Hagner, P. R., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3500.3500 · Cited by 12
Self-citation
A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma
Rasco, D. W., Gandhi, A. K., James, A. J., Li, S., O'Mara, E. M., Chopra, R., DiMartino, J. F., & Shih, K. C. (2013) · Blood · doi:10.1182/blood.v122.21.2905.2905 · Cited by 9
Self-citation
IMiDs® Immunomodulatory Agents Regulate Interferon-Stimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance
Havens, C. G., Bjorklund, C. C., Kang, J., Ortiz, M., Fontanillo, C., Amatangelo, M. D., Lu, L., Neri, P. E., Lopez‐Girona, A., Bahlis, N. J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3432.3432 · Cited by 4
Self-citation

Sorted by citations

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537
“Consistent with our earlier finding that CC-122 and CC-220 were capable of degrading ZFs not affected by pomalidomide, all three thalidomide analogs exhibited distinct ZF degradation patterns across the ZF library (Fig.”
MethodInfluential
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Dong, G., Ding, Y., He, S., & Sheng, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00895 · Cited by 369
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Small-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 298
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Coiffier, B., & Sarkozy, C. (2016) · Hematology · doi:10.1182/asheducation-2016.1.366 · Cited by 294

See all 207

Authors: Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., Raymon, H., Narla, R. K., Barnes, L., Khambatta, G., Chiu, H., Kosek, J., Kang, J., Amantangelo, M. D., Waldman, M., Lopez-Girona, A., Cai, T., Pourdehnad, M., Trotter, M., Daniel, T. O., Schafer, P. H., Klippel, A., Thakurta, A., Chopra, R., & Gandhi, A. K.
Affiliations: Celgene (United States) (US)
Celgene Corporation, Sevilla, Spain;
Celgene Corporation, San Diego, CA; and
Celgene Corporation, San Francisco, CA
ORCID: Hagner, Patrick R.
Fontanillo, Celia
Wang, Maria
Couto, Suzana
Bjorklund, Chad
Lu, Gang
Rychak, Emily
Narla, Rama Krishna
Barnes, Leo
Khambatta, Gody
Chiu, Hsiling
Kang, Jian
Pourdehnad, Michael
Trotter, Matthew
Schafer, Peter H.
Klippel, Anke
Thakurta, Anjan
Gandhi, Anita K.
Venue: Blood
Publisher: American Society of Hematology
Published: 2015-08-06
Volume: 126
Issue: 6
Pages: 779-789
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2015-02-628669
PMC: PMC4528065
OpenAlex: W1628369270
Cited by: 203
References: 36
Citations by year: 2026: 9 · 2025: 20 · 2024: 20 · 2023: 24 · 2022: 21 · 2021: 30 · 2020: 24 · 2019: 12 · 2018: 18 · 2017: 12 · 2016: 11 · 2015: 2
FWCI: 6.37
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Cancer Research UK (11566)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords: cereblon, lenalidomide, pomalidomide, Aiolos, Ikaros, diffuse large B-cell lymphoma, interferon-stimulated genes, interferon response, ubiquitination, protein degradation, apoptosis, germinal center B-cell DLBCL, T cells, immunomodulators
MeSH terms: Lenalidomide, Animals, Antineoplastic Agents, B-Lymphocytes, Humans, Interferons, Peptide Hydrolases, Piperidones, T-Lymphocytes, Thalidomide, Signal Transduction, Gene Expression Regulation, Neoplastic, Lentivirus, Lymphoma, Large B-Cell, Diffuse, Mice, SCID, Molecular Mimicry, Xenograft Model Antitumor Assays, RNA, Small Interfering, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Interferon Regulatory Factor-7, Mice, Ikaros Transcription Factor, Quinazolinones, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks